PDS Biotechnology Corp. (PDSB)
1.09
-0.07
(-6.03%)
USD |
NASDAQ |
Oct 23, 12:48
PDS Biotechnology EPS Diluted (Quarterly) : -0.1752 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1752 |
| March 31, 2026 | -0.1324 |
| December 31, 2025 | -0.1405 |
| September 30, 2025 | -0.1922 |
| June 30, 2025 | -0.2055 |
| March 31, 2025 | -0.2095 |
| December 31, 2024 | -0.2104 |
| September 30, 2024 | -0.2914 |
| June 30, 2024 | -0.227 |
| March 31, 2024 | -0.3046 |
| December 31, 2023 | -0.3441 |
| September 30, 2023 | -0.351 |
| June 30, 2023 | -0.3745 |
| March 31, 2023 | -0.3175 |
| December 31, 2022 | -0.6653 |
| September 30, 2022 | -0.2609 |
| June 30, 2022 | -0.2045 |
| March 31, 2022 | -0.3239 |
| December 31, 2021 | -0.2222 |
| September 30, 2021 | -0.2449 |
| June 30, 2021 | -0.0254 |
| March 31, 2021 | -0.1369 |
| December 31, 2020 | -0.1809 |
| September 30, 2020 | -0.206 |
| June 30, 2020 | -0.1908 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.3864 |
| December 31, 2019 | -0.7911 |
| September 30, 2019 | -1.096 |
| June 30, 2019 | -0.7508 |
| March 31, 2019 | 1.474 |
| December 31, 2018 | -10.65 |
| September 30, 2018 | -0.454 |
| June 30, 2018 | -3.402 |
| March 31, 2018 | -0.238 |
| December 31, 2017 | -9.00 |
| September 30, 2017 | -7.40 |
| June 30, 2017 | -8.80 |
| March 31, 2017 | -8.40 |
| December 31, 2016 | -6.60 |
| September 30, 2016 | -7.40 |
| June 30, 2016 | -6.60 |
| March 31, 2016 | -6.40 |
| December 31, 2015 | -6.00 |
| September 30, 2015 | -8.301 |
| June 30, 2015 | -5.083 |
| March 31, 2015 | -3.603 |
| December 31, 2014 | -2.561 |
| September 30, 2014 | -2.716 |
| June 30, 2014 | -2.356 |
| March 31, 2014 | -2.007 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -9.751M |
| Total Expenses (Quarterly) | 9.751M |
| Enterprise Value | 63.64M |
| Earnings Yield | -58.74% |
| Normalized Earnings Yield | -58.74 |